IL1B and lung disorder: There are three types of reagents targeting IL‐1 that have been evaluated for anti‐inflammatory activity in the context of lung diseases: anakinra is an IL‐1 receptor antagonist,66 MEDI8968 is a humanised anti‐IL‐1R antibody, and canakinumab is an anti‐IL‐1β blocking antibody.